Literature DB >> 29313949

Cancer statistics, 2018.

Rebecca L Siegel1, Kimberly D Miller2, Ahmedin Jemal3.   

Abstract

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2014, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2015, were collected by the National Center for Health Statistics. In 2018, 1,735,350 new cancer cases and 609,640 cancer deaths are projected to occur in the United States. Over the past decade of data, the cancer incidence rate (2005-2014) was stable in women and declined by approximately 2% annually in men, while the cancer death rate (2006-2015) declined by about 1.5% annually in both men and women. The combined cancer death rate dropped continuously from 1991 to 2015 by a total of 26%, translating to approximately 2,378,600 fewer cancer deaths than would have been expected if death rates had remained at their peak. Of the 10 leading causes of death, only cancer declined from 2014 to 2015. In 2015, the cancer death rate was 14% higher in non-Hispanic blacks (NHBs) than non-Hispanic whites (NHWs) overall (death rate ratio [DRR], 1.14; 95% confidence interval [95% CI], 1.13-1.15), but the racial disparity was much larger for individuals aged <65 years (DRR, 1.31; 95% CI, 1.29-1.32) compared with those aged ≥65 years (DRR, 1.07; 95% CI, 1.06-1.09) and varied substantially by state. For example, the cancer death rate was lower in NHBs than NHWs in Massachusetts for all ages and in New York for individuals aged ≥65 years, whereas for those aged <65 years, it was 3 times higher in NHBs in the District of Columbia (DRR, 2.89; 95% CI, 2.16-3.91) and about 50% higher in Wisconsin (DRR, 1.78; 95% CI, 1.56-2.02), Kansas (DRR, 1.51; 95% CI, 1.25-1.81), Louisiana (DRR, 1.49; 95% CI, 1.38-1.60), Illinois (DRR, 1.48; 95% CI, 1.39-1.57), and California (DRR, 1.45; 95% CI, 1.38-1.54). Larger racial inequalities in young and middle-aged adults probably partly reflect less access to high-quality health care. CA Cancer J Clin 2018;68:7-30.
© 2018 American Cancer Society. © 2018 American Cancer Society.

Entities:  

Keywords:  cancer cases; cancer statistics; death rates; incidence; mortality

Mesh:

Year:  2018        PMID: 29313949     DOI: 10.3322/caac.21442

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  2000 in total

1.  [Expression of secreted frizzled-related protein 4 in DNA mismatch repair-deficient and mismatch repair-proficient colorectal cancers].

Authors:  Kexu Chen; Hanlin Liang; Jiewen Peng; Yanfang Zheng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

2.  PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.

Authors:  Kenji Zennami; Su Mi Choi; Ross Liao; Ying Li; Wikum Dinalankara; Luigi Marchionni; Fatema H Rafiqi; Akira Kurozumi; Koji Hatano; Shawn E Lupold
Journal:  Mol Cancer Res       Date:  2018-12-05       Impact factor: 5.852

3.  Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression.

Authors:  Bing Song; Su-Hong Park; Jonathan C Zhao; Ka-Wing Fong; Shangze Li; Yongik Lee; Yeqing A Yang; Subhasree Sridhar; Xiaodong Lu; Sarki A Abdulkadir; Robert L Vessella; Colm Morrissey; Timothy M Kuzel; William Catalona; Ximing Yang; Jindan Yu
Journal:  J Clin Invest       Date:  2018-12-18       Impact factor: 14.808

4.  Long-Term Oncologic Outcomes of Uterine-Preserving Surgery in Young Women With Stage Ib1 Cervical Cancer.

Authors:  Jill H Tseng; Alessia Aloisi; Yukio Sonoda; Ginger J Gardner; Oliver Zivanovic; Nadeem R Abu-Rustum; Mario M Leitao
Journal:  Int J Gynecol Cancer       Date:  2018-09       Impact factor: 3.437

5.  MiR-125b attenuates human hepatocellular carcinoma malignancy through targeting SIRT6.

Authors:  Shi Song; Yuxia Yang; Minghui Liu; Boya Liu; Xin Yang; Miao Yu; Hao Qi; Mengmeng Ren; Zhe Wang; Junhua Zou; Feng Li; Xiaojuan Du; Hongquan Zhang; Jianyuan Luo
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

6.  Metabolic Changes in Androgen-Deprived Nondiabetic Men With Prostate Cancer Are Not Mediated by Cytokines or aP2.

Authors:  Thiago Gagliano-Jucá; M Furkan Burak; Karol M Pencina; Zhuoying Li; Robert R Edwards; Thomas G Travison; Shehzad Basaria
Journal:  J Clin Endocrinol Metab       Date:  2018-10-01       Impact factor: 5.958

7.  Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.

Authors:  Krishna B Singh; Xinhua Ji; Shivendra V Singh
Journal:  Mol Cancer Ther       Date:  2018-07-20       Impact factor: 6.261

8.  Dipeptidyl Peptidase 9 Increases Chemoresistance and is an Indicator of Poor Prognosis in Colorectal Cancer.

Authors:  Kazuhiro Saso; Norikatsu Miyoshi; Shiki Fujino; Masaru Sasaki; Masayoshi Yasui; Masayuki Ohue; Takayuki Ogino; Hidekazu Takahashi; Mamoru Uemura; Chu Matsuda; Tsunekazu Mizushima; Yuichiro Doki; Hidetoshi Eguchi
Journal:  Ann Surg Oncol       Date:  2020-07-30       Impact factor: 5.344

9.  Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.

Authors:  R A Juergens; C Mariano; J Jolivet; N Finn; J Rothenstein; M N Reaume; A Faghih; C Labbé; S Owen; F A Shepherd; J Villeneuve; F Romeyer; F Pettersson; C Butts
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

Review 10.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.